Background-A drug delivery system that constitutively and effectively retains cardioprotective reagents in the targeted myocardium has long been sought to treat acute myocardial infarction. We hypothesized that a scaffold-free induced adipocyte cell-sheet (iACS), transplanted on the surface of the heart, might intramyocardially secrete multiple cardioprotective factors including adiponectin (APN), consequently attenuating functional deterioration after acute myocardial infarction. Methods and Results-Induced ACS were generated from adipose tissue-derived cells of wild-type (WT) mice (C57BL/6J), which secreted abundant APN, hepatocyte growth factor, and vascular endothelial growth factor in vitro.
D espite recent progress in medical and surgical treatments for heart failure, acute myocardial infarction (AMI) and the subsequent deterioration of cardiac performance is still a major cause of death, worldwide. An array of cardioprotective reagents have been identified to be effective in ameliorating AMI by administrating into the infarcted myocardium in experimental models. 1 However, these reagents have failed to show consistent therapeutic efficacy in several clinical trials, probably due to poor retention or rapid inactivation of reagents in the injured myocardial tissues. 1 Therefore, a drug delivery system (DDS) that retains cardioprotective reagents in the targeted myocardial area has long been sought.
Intramyocardially transplanted autologous stem cells secrete various cardioprotective cytokines and growth factors, enhance angiogenesis, reduce fibrosis, attenuate apoptosis, and suppress myocyte hypertrophy, consequently ameliorating AMI in a paracrine manner. 2, 3 However, cell transplantation for AMI has shown only modest therapeutic efficacy in large-scale clinical studies. It appears to result from insufficient paracrine effects whose magnitude and figure are largely affected by the cell delivery method or transplanted cell source. 4 To enhance the survival and functions of the transplanted cells, we developed a cell-sheet-based delivery method in which isolated cells, cultivated in vitro as a sheet without a scaffold, are simply placed on the surface of the myocardium. This treatment enhances the paracrine effects, resulting in better therapeutic efficacy. 5, 6 Adipocytes differentiated from adipose tissue-derived stromal-vascular fraction (SVF) cells are a promising cell source for treating AMI because as they secrete hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and, importantly, adiponectin (APN). 7, 8 APN is a circulating secretory protein that has multiple cardioprotective effects, including the attenuation of inflammation, fibrosis, and myocyte hypertrophy. 8, 9 However, the clinical use of APN for treating AMI has been hampered by the lack of effective systems for delivering APN to the heart. We hypothesized that using cell-sheet technology to deliver adipocytes that secrete multiple cardioprotective factors, including APN, might attenuate the functional deterioration after AMI.
Methods
Animal care complied with the "Guide for the Care and Use of Laboratory Animals" (NIH publication No. 85 to 23, revised 1996) . Experimental protocols were approved by the Ethics Review Committee for Animal Experimentation of Osaka University Graduate School of Medicine.
Generation and Assessment of Adipocyte Cell-Sheet
The SVF cells of adipose tissue were isolated from wild-type (WT; male C57BL/6J) or APN-knockout (KO) mice, 10 as described previously. 11 The isolated SVF cells were cultured until they become confluent on Upcell dishes (CellSeed Inc, Tokyo, Japan). Differentiation into adipocytes was induced by insulin, dexamethasone, isobutylmethylxanthine, and pioglitazone (Sigma-Aldrich, MO). Incubation at 20°C induced the cells to detach from the culture dishes, yielding a scaffold-free cell-sheet, which we call an "induced adipocyte cell-sheet" (iACS). The secretion of HGF, VEGF, leptin, interleukin (IL)-6, tumor necrosis factor (TNF)-␣, and IL-10 into the culture supernatant was assessed by ELISA. Before transplantation, WT mouse-derived iACS (WT-iACS) and APN-KO mouse-derived iACS (KO-iACS) were labeled with the use of a PKH26 kit (Sigma-Aldrich).
Generation of AMI Model and Cell-Sheet Transplantation
An AMI model was generated by permanent ligation of the left anterior descending artery (LAD) in male C57BL/6J mice, 10 to 15 weeks old. 12 The mice were anesthetized by isoflurane inhalation (Mylan Inc). Five minutes after the LAD ligation, WT-iACS (W group, nϭ40) or KO-iACS (K group, nϭ40) was grafted onto the surface of the anterior left ventricular (LV) wall, or a sham operation was performed (C group, nϭ43). The mice were euthanized at 2 and 28 days after LAD ligation and cell-sheet transplantation.
Assessment of Cardiac Function and Survival
Cardiac function was assessed with the use of an echocardiography system equipped with a 12-MHz transducer (GE Healthcare) at 4 weeks. The LV dimensions were measured, and LV ejection fraction was calculated as (LVDd 3 ϪLVDs 3 )/LVDd 3 ϫ100, where LVDd and LVDs are the LV end-diastolic and end-systolic dimensions, respectively. 12 The mice were housed in a temperature-controlled incubator for 50 days after treatment to determine their survival.
Histological Analysis
Freshly excised hearts were stained with 1% 2,3,5-triphenyltetrazolium chloride (TTC; Sigma-Aldrich). The red-stained infarct area was quantified by computerized planimetry, using MetaMorph Software (Molecular Devices). Frozen sections (8 m) of hearts and cell-sheets were stained with antibodies against APN (Otsuka Pharmaceutical, Tokushima, Japan) or CD11b (Abcam, Cambridge, UK). The secondary antibody was Alexa 488 goat anti-rabbit (Life Technologies). Counterstaining was performed with 6-diamidino-2phenylindole (Life Technologies). To analyze the myocardial colla-gen accumulation, heart sections were stained with Masson trichrome. The collagen volume fraction was calculated in the peri-infarct area. To assess cardiomyocyte diameter, heart sections were stained with periodic acid-Schiff. MetaMorph Software was used for the quantitative morphometric analysis.
Cytokine Antibody Array
Proteins were isolated from whole-heart samples and analyzed using a Milliplex Mouse Cytokine/Chemokine Panel Premixed 32Plex, according to the manufacturer's instructions (Millipore).
Quantitative Real-Time PCR
Total RNA was isolated from the peri-infarct area by use of the RNeasy Mini Kit and reverse-transcribed, using Omniscript Reverse transcriptase (Qiagen, Hilden, Germany). Quantitative PCR was performed with the PCR System (Life Technologies). The expression of each mRNA was normalized to that of glyceraldehyde-3phosphate dehydrogenase.
Statistical Analysis
Data are expressed as the meanϮSEM. The data distributions were checked for normality with the Shapiro-Wilk test and for equality of variances with the Bartlett test. Comparisons between 2 groups were made using the unpaired t test or the Wilcoxon-Mann-Whitney U test, as appropriate. For comparisons among 3 groups, we used 1-way ANOVA, followed by Fisher protected least-significance difference test or the Kruskal-Wallis test, followed by the post hoc pairwise Wilcoxon-Mann-Whitney U test, as appropriate. The survival curves were prepared by using the Kaplan-Meier method and were compared using the overall log-rank test, followed by the post hoc pairwise log-rank test. The multiplicity in pairwise comparisons was corrected by the Benjamin-Hochberg procedure. All probability values are 2-sided, and values of PϽ0.05 were considered to indicate statistical significance. Statistical analysis was performed with the StatView 5.0 Program (Abacus Concepts, Berkeley, CA) and the R program. 13 An expanded Methods section can be found in the online-only Data Supplement.
Results

Characterization of the Adipocyte Cell-Sheets
Most SVF cells differentiated into mature adipocytes bearing oil droplets by 7 days after differentiation induction. Induced ACS or undifferentiated SVF cell-sheets were then generated by lowering the temperature ( Figure 1A ). Each iACS was approximately 7 mm in diameter ( Figure 1B ) and 100 m thick ( Figure 1C ). WT-iACS expressed abundant APN in the cytoplasm and extracellular matrix around the oil-dropletrich adipocytes, as assessed by immunohistochemistry (Figure 1D ) and ELISA ( Figure 1E ). In contrast, neither the SVF cell-sheets of either origin nor the KO-iACS expressed APN ( Figure 1D and 1E). The ELISA showed abundant HGF expression in WT-iACS and KO-iACS, which was downregulated compared with the WT SVF cells ( Figure 1F ). The secretion of VEGF and leptin was remarkably enhanced by the SVF cell differentiation into adipocytes. IL-6 and IL-10 were secreted by the WT-iACS and WT-SVF cells at similar levels, which were lower than the levels secreted by KO-iACS. The secretion of TNF-␣ was not evident in any group because the cell-free culture medium also contained 2.29 pg/mL TNF-␣.
Transplanted Induced ACS Supplied APN to the Myocardium
WT-iACS were transplanted onto the heart of intact APN-KO mice to evaluate behavior of the WT-iACS, including APN production. Immediately after transplantation, the WT-iACS expressed APN epicardially at the anterior LV wall, but it was not expressed intramyocardially ( Figure 2A ). Four weeks after transplantation, the WT-iACS had survived, was approximately 600 m thick, and contained adipocytes and connective tissue. At this time, the WT-iACS was tightly integrated with the epicardium, but no invasion of transplanted cells into the recipient myocardium was observed ( Figure 2B and 2E). APN was expressed in the cytoplasm of scattered surviving WT-iACS cells and in the myocardium close to the WT-iACS ( Figure 2B and 2G) . In contrast, although the KO-iACS transplanted into KO mice survived ( Figure 2C and 2F), they did not express or secrete APN ( Figure 2C ). When WT-iACS was transplanted into KO mice, APN was detected in the plasma 1 and 3 months later, but it was not detected in the plasma of KO mice with the KO-iACS implant ( Figure 2H ).
Induced ACS Implantation Reduced Inflammatory Responses and Infarct Area 2 Days After MI
The anti-inflammatory effects of WT-iACS were evaluated by cytokine antibody array analysis of whole-heart lysates from the AMI mice that were treated with WT-iACS (W), KO-iACS (K), or no iACS (C) groups at 2 days after implantation (Table) . A significantly lower level of the inflammatory factor granulocyte macrophage colonystimulating factor (GM-CSF) was observed in the W group compared with the others, and the levels of other inflammatory cytokines, keratinocyte chemoattractant, IL-6, granulocyte (G)-CSF, and monocyte chemotactic protein-1 (MCP-1) showed a trend toward downregulation in the W group. Quantitative RT-PCR showed that the TNF␣ mRNA levels were lower in the peri-infarct area of the W group than in that of the K and C groups, which reached statistical significance in the W group ( Figure 3A) . Furthermore, immunohistochem- istry for CD11b showed significantly fewer infiltrated macrophages in the peri-infarct area of the W and K groups than in that of the C group ( Figure 3B ). Finally, a semiquantitative assessment by TTC staining showed that the infarct area was significantly smaller in the W group than in the K and C groups (Figure 4 ).
Induced ACS Transplantation Suppressed LV Remodeling Development at 4 Weeks After MI
Four weeks after LAD ligation, the C group showed a typical MI with a large anterior LV scar, dilatation of the LV cavity, and cardiomyocyte hypertrophy. By comparison, the LV of the W group was less dilated, and the anterior wall was thicker ( Figure 5A ). The diameter of the cardiomyocytes was significantly smaller in the W group ( Figure 5B and 5C) , and there was less collagen accumulation ( Figure 5D and 5E). There was no difference in capillary density among the groups (online-only Data Supplement Figure 1 ).
Therapeutic Effects of Induced ACS Transplantation on Cardiac Performance and Survival at 4 Weeks After MI
Cardiac performance was evaluated by 2D echocardiography 4 weeks after implantation. Both the diastolic and systolic LV dimensions were smaller in the W group than the others, but the difference was not significant. In contrast, LV ejection fraction was significantly greater in the W group than the K and C groups ( Figure 6A ). In addition, in a WT-iACStransplanted rat model of acute MI, invasive hemodynamic analysis showed higher end-systolic pulmonary vascular resistance and dP/dtmax and lower dP/dtmin, compared with sham transplantation (online-only Data Supplement Figure  2 ). Mortality was substantial until 14 days after LAD ligation in the K and C groups. In contrast, in the W group, there was little mortality 5 days after MI and thus a significant difference in survival ( Figure 6B ).
Discussion
We developed an adipocyte cell-sheet-based DDS for the heart. These sheets, which are generated from adipose tissuederived SVF cells induced to differentiate in culture, secreted multiple cardioprotective factors in vitro, including APN, HGF, and VEGF. Although adipose tissue-derived SVF cells had no ability to secrete APN, after the differentiation to adipocytes, the cells started to secrete APN in addition to HGF and VEGF. APN was secreted from the iACS into the myocardium and blood for at least 3 months, probably along with HGF, VEGF, leptin, and IL-10. In a mouse model of AMI, WT-iACS significantly decreased inflammation and myocardial infarct size at the acute stage. Furthermore, myocardial fibrosis and cardiomyocyte hypertrophy were significantly attenuated at the late stage, which led to improved cardiac performance and a better post-MI survival rate. Importantly, the transplantation of KO-iACS onto infarcted hearts resulted in only modest therapeutic benefits, indicating that APN plays a pivotal role in attenuating the AMI in this experimental model.
There have been many experimental and clinical studies in which the administration of exogenous proteins, including APN, induced angiogenesis, reversed remodeling, and improved cardiac function. 1, 14 The issues in this method may be that naked protein is delivered to the heart and is often poorly retained or quickly inactivated and therefore lacks long-term efficacy. 15 MI is a progressive disease, characterized by massive ischemic necrosis of the myocardial tissue and subsequent inflammation. This leads to cardiac remodeling that exacerbates the oxygen shortage in the surviving cardiac tissue. These pathological and functional deteriorations eventually cause end-stage heart failure. A constitutive and balanced supply of cardioprotective reagents, rather than the 1-time administration of a single reagent, should inhibit this vicious circle. The direct injection of plasmid vectors encoding targeted reagents and the transplantation of genetically modified cells can provide a controlled and stable supply of reagents over the long term; however, their clinical use is limited because the safety of the viral systems used as vectors for the plasmids and of modifying cells for transplant is still a concern. 16 Encapsulation as the DDS for biomaterials is another attractive approach; however, difficulty in controlling the rate of reagent release, such as the occurrence of an initial burst release, limits its therapeutic efficacy. 17, 18 In addition, biodegradable polymers that carry reagents may induce the deposition of extracellular matrix and myocardial inflamma- tion, leading to pathological fibrotic states. 19 Our cell-sheetbased DDS constitutively and effectively delivered multiple cardioprotective factors over the long term, leading to reverse LV remodeling after MI, without gene modification or scaffold use. Thus, this strategy might be more practical and effective than other methods for delivering therapeutic proteins for treating MI in the clinical arena. It is possible that the delivery of multiple growth factors will improve therapeutic efficacy over the delivery of a single factor. This hypothesis is supported by a study showing that the combination of HGF and VEGF leads to better engraftment and significant angiogenesis, compared with either factor alone. 20 In our study, the KO-iACS, which secreted HGF and VEGF but not APN, reduced macrophage infiltration but did not induce functional or survival benefits. These benefits were conferred by the WT-iACS, which produced APN, suggesting that APNЈs benefits are different from and in addition to those of known paracrine mediators, such as HGF or VEGF.
APN is a protective factor against cardiovascular diseases. 9, 21 In particular, its anti-inflammatory properties may be the major reason for its beneficial effects on cardiovascular disorders, because APN-deficient mice exhibit increased TNF-␣ production and myocardial apoptosis in response to ischemia reperfusion. 22, 23 We observed that the expression of TNF-␣ in the AMI heart was significantly reduced by transplanting WT-iACS but not KO-iACS, which secrete similar levels of the same cytokines, except for APN, suggesting that the direct anti-inflammatory effects of APN played a key role in the attenuated inflammation in this study. In addition, the infarct size was significantly smaller in the WT-iACS-transplanted hearts than in the KO-iACS-transplanted ones. Infarct size is determined by multiple factors, including the magnitude of ischemic stimuli, degree of inflammation, and amount of apoptosis. The beneficial effects of APN on inflammation after the iACS treatment may have led to the attenuated infarct size and suppressed the exacerbation of cardiac performance. In addition, APN has been shown to directly inhibit the hypertrophic response in myocytes. 24 Therefore, the combined direct and indirect actions of APN probably inhibit the development of pathological hypertrophy and preserve myocardial mass. Although we traced the iACS-derived APN by using APN-KO mice to demonstrate the APN delivery, HGF, VEGF, and other beneficial growth factors are probably also released constitutively by the iACS. Thus, iACS can provide a combined and balanced release of multiple paracrine mediators that may synergistically augment therapeutic benefits. 20, 23 On the other hand, APN is reported to have proangiogenic potential. 9 In fact, VEGF secretion from WT-iACS and KO-iACS were also greater compared with undifferentiated WT-SVF cell-sheet in this study. However, the capillary density in the treated myocardium, which was assessed by CD31 immunohistolabeling, was not higher at 28 days after WT-iACS transplantation, compared with post-KO-iACS transplantation and sham transplantation. These inconsistent findings may result from the AMI model in which neoangiogenesis substantially occurs in the treated area, not allowing dissection of the slight difference in capillary density between the experimental groups. Rather, the findings of this study suggested that anti-inflammatory effects were the major mechanism for the improvement after WT-iACS transplantation in this model. Another disease model such as dilated cardiomyopathy and old myocardial infarction may be more appropriate to evaluate angiogenic property of iACS treatment.
The treatment strategy for AMI studied here is not directly applicable to the clinical arena, because the time required to isolate, cultivate, or manipulate cells in vitro is not available for AMI, which requires immediate treatment. However, the finding that this therapy yielded marked cardioprotective effects through constitutive APN production should be beneficial for treating other types of cardiac pathologies, such as the chronic phase of MI, dilated cardiomyopathy, or myocarditis. In addition, this sophisticated cell-sheet, which elevates the systemic APN level for some time, might also be effective for treating systemic disorders such as obesity-linked cardiovascular or metabolic disorders, although this possibility will require further investigation. 9, 21 A potential limitation of this study is that the small sample sizes in our experiments limit their statistical power. Thus, the apparent absence of a statistical difference may be due to the lack of statistical power to detect small differences; therefore our negative results may have no meaning. Nevertheless, despite the small sample sizes, we at least clearly showed that APN was delivered by WT-iACS and that the therapeutic effect of WT-iACS implantation was attained through APN. Furthermore, we conducted multiple statistical tests for significance separately for each outcome in a univariate manner, although we adjusted for multiple pairwise testing between groups within each outcome. Such tests for multiple outcomes could lead to the inflation of the type I error probability in making treatment effect claims.
In the present study, we focused on the delivery of cytokines by iACS. However, we speculate that other mechanisms may also contribute to the functional recovery after iACS implantation. Tateno et al 25 clearly showed that cell transplantation induces the recipient tissue to produce angiogenic factors, including IL-1␤, even though the transplanted cells do not produce sufficient levels of cytokines to promote angiogenesis directly. Similarly, iACS may stimulate recipient tissue, thus activating cells in the recipient to produce angiogenic cytokines. Further study will be required to elucidate what cross-talk occurs between the iACS and the recipient myocardium. Figure 6 . Wild-type induced adipocyte cell-sheet (WT-iACS) improved cardiac function and survival after myocardial infarction. A, Evaluation of cardiac performance 4 weeks after treatment (nϭ18 each). In the W group, the left ventricular end-systolic dimension was smaller and the ejection fraction significantly higher than in the other groups (PϽ0.05, Kruskal-Wallis test). *PϽ0.05 versus C group. †PϽ0.05 versus K group, post hoc Wilcoxon-Mann-Whitney U test. B, Survival rates after treatment. There was no significant difference between the C (nϭ25) and K groups (nϭ26). The W group (nϭ24) showed significantly better survival than the other groups (PϽ0.05, overall log-rank test). *PϽ0.05 versus C group, †PϽ0.05 versus K group, post hoc log-rank test.
In summary, iACS may be a powerful DDS for cytokines, including APN, HGF, and VEGF. The implantation of iACS onto the infarcted mouse heart reduces the infarct size, inflammation, and LV remodeling. This method is probably adaptable as a novel DDS for treating heart failure.
